EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls
While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations…
While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations…
A drug developed by the French company MedDay Pharmaceuticals has failed to treat progressive forms…
Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis…
An antibody that blocks the action of a hidden viral protein encoded by our genome…
Altheia Science, based in Milan, has raised €17M to fund the development of gene therapies…
Spanish biotech Bionure has started an early stage trial of a new drug to treat…
GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in…
Just months after the EMA rejected its therapy for Duchenne muscular dystrophy, Swiss company Santhera…
Rewind Therapeutics has received a boost in the development of its multiple sclerosis therapies, raising a…
In our last BIO Europe interview, I caught up with CEO Timm Jessen of Topas…
Topas Therapeutics received an extra €4M from Boehringer Ingelheim Venture Fund to help its autoimmune disease candidates…
A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in…